ASH MPN Spotlight | Conferences

Ivosidenib Demonstrates Responses in More Than 40% in Relapsed/Refractory IDH+ AML

December 16, 2017

Ivosidenib (AG-120), an IDH1 inhibitor, demonstrated an objective response rate (ORR) of 41.6% in patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to findings from a single-arm phase I study.

Pegylated Interferon Alfa-2a Active in Hydroxyurea-Resistant PV and ET

December 16, 2017

Treatment with pegylated interferon alfa-2a led to objective responses in about two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia, a phase II study of salvage therapy showed.

Sotatercept in Patients With MPN-Associated Myelofibrosis and Anemia

December 16, 2017

Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

December 15, 2017

A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response compared with hydroxyurea (Hydrea) in patients with polycythemia vera, according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.

Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis

December 15, 2017

The investigational activin receptor IIA ligand trap sotatercept safely increases hemoglobin levels in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis, both when used alone and in combination with ruxolitinib (Jakafi).

Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV

December 12, 2017

Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

BLU-285 Induces Responses in Patients With Systemic Mastocytosis

December 11, 2017

Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells, according to data from an ongoing phase I trial.